Treatment of Localised Renal Cell Carcinoma in Patients with a Germline VHL Gene Variant

This protocol addresses localised renal cell carcinoma occurring in patients who carry a germline variant in the von Hippel-Lindau (VHL) gene. This hereditary genetic background identifies a specific sub-population for whom a distinct management pathway applies.

For patients in this setting who do not require immediate surgery, a targeted medical therapy is available. This approach may allow eligible patients to avoid surgical intervention.

Full regimen details, eligibility criteria, dosing, and clinical guidance are available in the structured protocol below.